AbbVie registers Phase 3 trial of etentamig vs Dara-CyBorD in AL amyloidosis
New Phase 3 study will compare etentamig to daratumumab-based combination therapy in newly diagnosed amyloid light chain amyloidosis patients.
This week brought one new AbbVie trial registration to the clinical trials registry.
- AbbVie has registered a Phase 3 study (NCT07793422) evaluating etentamig compared to daratumumab plus cyclophosphamide plus bortezomib plus dexamethasone (Dara-CyBorD) in participants with newly diagnosed AL amyloidosis.1 The study is not yet recruiting1 with an estimated start date and plans to enroll approximately 370 participants at approximately 130 sites worldwide.1 The trial includes a safety run-in phase followed by a randomized portion, with the comparator arm receiving daratumumab plus cyclophosphamide plus bortezomib plus dexamethasone (Dara-CyBorD) in accordance with the local approved label.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.